Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
Status:
Withdrawn
Trial end date:
2018-10-10
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to assess whether celecoxib can reduce the change in
collagen alignment and inflammatory response in the tumor tissue of primary breast cancer
patients with invasive breast carcinoma after 2 weeks of oral intake.